Indian Patent Office Revokes Novartis' Vymada Patent, Opening Door for Generic Competition
核心洞察
The Indian Patent Office revoked Novartis' patent for Vymada (搜索) (Entresto), a heart failure drug generating $7.8 billion in global sales, citing lack of novelty and inventive step.
The ruling removes legal barriers for domestic pharmaceutical companies including Natco, Torrent Pharma, MSN Labs (搜索), and Eris Lifesciences (搜索) to market generic versions.
The decision invoked Section 3(d) of India's Patents Act, designed to prevent "evergreening" of patents, marking a rare application of this provision in recent years.
The Indian Patent Office has delivered a significant blow to Novartis by revoking the patent for its blockbuster cardiac drug Vymada (搜索), potentially transforming the heart failure treatment landscape in India. The September 12 ruling by Deputy Controller of Patents and Designs D Usha Rao cited lack of novelty and inventive step as grounds for the revocation, opening the door for widespread generic competition.
Patent Revocation Details
Vymada (搜索), marketed internationally as Entresto, combines sacubitril and valsartan and represents a major revenue stream for Novartis, generating $7.8 billion in global sales last year. The Swiss pharmaceutical giant's patent, filed in 2007 and granted in December 2022, faced immediate challenges from domestic Indian companies.
The patent office ruling stated that Novartis "failed to disclose any demonstrated advantages or technical advancement of the claimed supramolecular complex over the combination already disclosed." The order specifically noted that "no experimental data, comparative studies or technical rationale have been provided to substantiate any enhanced efficacy" and that "no improved therapeutic efficacy has been shown."
Section 3(d) Invocation
The revocation marks a rare application of Section 3(d) of India's Patents Act, a provision designed to prevent "evergreening" of patents. This clause gained international attention in 2013 when Novartis lost its patent claim on the cancer drug Glivec under the same provision.
Domestic pharmaceutical companies, including IPCA and Micro Labs, supported by the Indian Pharmaceutical Alliance (搜索), challenged the patent at the post-grant stage. They argued that the patent claim violated Section 3(d), representing an unusual move by the industry body to directly oppose a multinational's patent.
Market Impact and Generic Competition
The ruling removes significant legal uncertainty for several Indian companies that had launched generic versions of the drug "at risk," including Natco, Torrent Pharma, MSN Labs (搜索), and Eris Lifesciences (搜索). These companies had previously faced court restraints following litigation by Novartis and operated under constant threat of legal challenge.
"Companies are now free to launch, with more players expected to follow, bringing down the price of the therapy further," an industry expert told The Times of India. The decision is expected to trigger a wave of new market entrants, potentially driving down treatment costs for thousands of Indian patients with hypertension and heart failure.
Legal Proceedings and Future Outlook
Legal sources noted that Novartis abstained from the final hearing, with the decision based largely on written submissions from both parties. The company has not yet responded to the ruling but is widely expected to challenge the patent office decision in court.
The revocation was issued under multiple provisions of the Patents Act, 1970, including Section 25(2)(b) for lack of novelty, Section 25(2)(c) for prior claiming, Section 25(2)(e) for lack of inventive step, and Section 25(2)(g) for insufficient description of the invention. Patent No. 414518 was formally revoked and the case disposed of under these provisions.
This landmark ruling continues the ongoing tension between global pharmaceutical companies and India's patent regime, which has consistently prioritized access to affordable medicines for its population.